{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:52:22Z","timestamp":1772164342278,"version":"3.50.1"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Excessive bone destruction is a major cause of morbidity in myeloma patients. However, the biological mechanisms involved in the pathogenesis of myeloma-induced bone disease are not fully understood. Heparanase, an enzyme that cleaves the heparan sulfate chains of proteoglycans, is upregulated in a variety of human tumors, including multiple myeloma. We previously showed that heparanase promotes robust myeloma tumor growth and supports spontaneous metastasis of tumor cells to bone. In the present study, we show, for the first time, that the expression of heparanase by myeloma tumor cells remarkably enhances bone destruction locally within the tumor microenvironment. In addition, enhanced heparanase expression in the primary tumor also stimulated systemic osteoclastogenesis and osteolysis, thus mimicking the systemic osteoporosis often seen in myeloma patients. These effects occur, at least in part, as the result of a significant elevation in the expression and secretion of receptor activator of NF-\u03baB ligand (RANKL) by heparanase-expressing myeloma cells. Moreover, analysis of bone marrow biopsies from myeloma patients reveals a positive correlation between the level of expression of heparanase and RANKL. Together, these discoveries reveal a novel and key role for heparanase in promoting tumor osteolysis and show that RANKL is central to the mechanism of heparanase-mediated osteolysis in myeloma. Cancer Res; 70(21); 8329\u201338. \u00a92010 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-2179","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T22:31:06Z","timestamp":1288132266000},"page":"8329-8338","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Heparanase Enhances Local and Systemic Osteolysis in Multiple Myeloma by Upregulating the Expression and Secretion of RANKL"],"prefix":"10.1158","volume":"70","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"},{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}]},{"given":"Yongsheng","family":"Ren","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}]},{"given":"Vishnu C.","family":"Ramani","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}]},{"given":"Li","family":"Nan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}]},{"given":"Larry J.","family":"Suva","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}]},{"given":"Ralph D.","family":"Sanderson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"},{"name":"Authors' Affiliations:\u20081Department of Pathology and 2Comprehensive Cancer Center and the Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama and 3Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}]}],"member":"1086","published-online":{"date-parts":[[2010,10,31]]},"reference":[{"key":"2022061702421679000_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.18553\/jmcp.2008.14.S7-A.7","article-title":"Pathophysiological underpinnings of multiple myeloma progression","volume":"14","author":"Jagannath","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"2022061702421679000_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"2022061702421679000_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"2022061702421679000_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1359\/jbmr.090901","article-title":"Myeloma bone disease","volume":"24","author":"Sanderson","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2022061702421679000_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.biocel.2006.06.004","article-title":"Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis","volume":"38","author":"Ilan","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"2022061702421679000_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.tibs.2009.06.005","article-title":"Heparanase: busy at the cell surface","volume":"34","author":"Fux","year":"2009","journal-title":"Trends Biochem Sci"},{"key":"2022061702421679000_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3727\/096504008785114138","article-title":"Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study","volume":"17","author":"Chen","year":"2008","journal-title":"Oncol Res"},{"key":"2022061702421679000_bib8","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1007\/s11605-008-0628-2","article-title":"High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF","volume":"12","author":"Hoffmann","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2022061702421679000_bib9","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.23680","article-title":"Heparanase is overexpressed in lung cancer and correlates inversely with patient survival","volume":"113","author":"Cohen","year":"2008","journal-title":"Cancer"},{"key":"2022061702421679000_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1593\/neo.07875","article-title":"Clinical significance of urine heparanase in bladder cancer progression","volume":"10","author":"Shafat","year":"2008","journal-title":"Neoplasia"},{"key":"2022061702421679000_bib11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-07-1866","article-title":"Function of heparanase in prostate tumorigenesis: potential for therapy","volume":"14","author":"Lerner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702421679000_bib12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/ijc.21552","article-title":"Heparanase promotes growth, angiogenesis and survival of primary breast tumors","volume":"118","author":"Cohen","year":"2006","journal-title":"Int J Cancer"},{"key":"2022061702421679000_bib13","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1182\/blood-2006-08-043232","article-title":"Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma","volume":"109","author":"Mahtouk","year":"2007","journal-title":"Blood"},{"key":"2022061702421679000_bib14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jso.20097","article-title":"Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis","volume":"87","author":"Sato","year":"2004","journal-title":"J Surg Oncol"},{"key":"2022061702421679000_bib15","first-page":"5968","article-title":"Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis","volume":"9","author":"Xu","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2022061702421679000_bib16","first-page":"1299","article-title":"The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma","volume":"7","author":"El-Assal","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2022061702421679000_bib17","first-page":"4655","article-title":"Heparanase expression in primary and metastatic pancreatic cancer","volume":"61","author":"Koliopanos","year":"2001","journal-title":"Cancer Res"},{"key":"2022061702421679000_bib18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1182\/blood-2004-06-2141","article-title":"Heparanase promotes the spontaneous metastasis of myeloma cells to bone","volume":"105","author":"Yang","year":"2005","journal-title":"Blood"},{"key":"2022061702421679000_bib19","doi-asserted-by":"crossref","first-page":"13326","DOI":"10.1074\/jbc.M611259200","article-title":"Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis","volume":"282","author":"Yang","year":"2007","journal-title":"J Biol Chem"},{"key":"2022061702421679000_bib20","first-page":"8749","article-title":"High heparanase activity in multiple myeloma is associated with elevated microvessel density","volume":"63","author":"Kelly","year":"2003","journal-title":"Cancer Res"},{"key":"2022061702421679000_bib21","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2009-07-234757","article-title":"Heparanase enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis","volume":"115","author":"Purushothaman","year":"2010","journal-title":"Blood"},{"key":"2022061702421679000_bib22","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1158\/0008-5472.CAN-05-0749","article-title":"Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases","volume":"65","author":"Kelly","year":"2005","journal-title":"Cancer Res"},{"key":"2022061702421679000_bib23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.16","article-title":"Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis","volume":"25","author":"Kelly","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2022061702421679000_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.canlet.2008.04.008","article-title":"Heparanase promotes bone destruction and invasiveness in prostate cancer","volume":"268","author":"Zhou","year":"2008","journal-title":"Cancer Lett"},{"key":"2022061702421679000_bib25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/jcp.20625","article-title":"Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass","volume":"207","author":"Kram","year":"2006","journal-title":"J Cell Physiol"},{"key":"2022061702421679000_bib26","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.V96.7.2528","article-title":"Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins","volume":"96","author":"Borset","year":"2000","journal-title":"Blood"},{"key":"2022061702421679000_bib27","doi-asserted-by":"crossref","first-page":"32628","DOI":"10.1074\/jbc.M806266200","article-title":"Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma","volume":"283","author":"Purushothaman","year":"2008","journal-title":"J Biol Chem"},{"key":"2022061702421679000_bib28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V100.2.610","article-title":"Soluble syndecan-1 promotes growth of myeloma tumors in vivo","volume":"100","author":"Yang","year":"2002","journal-title":"Blood"},{"key":"2022061702421679000_bib29","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood-2007-04-082495","article-title":"The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"2022061702421679000_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1359\/jbmr.1999.14.7.1167","article-title":"Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus","volume":"14","author":"Hildebrand","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2022061702421679000_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00223-004-0074-4","article-title":"Increased RANKL\/OPG mRNA ratio in iliac bone biopsies from women with hip fractures","volume":"76","author":"Abdallah","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"2022061702421679000_bib32","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.0812801106","article-title":"Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells","volume":"106","author":"Lee","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702421679000_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"2022061702421679000_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00432-004-0578-3","article-title":"Expression of receptor activator of NF-\u03baB ligand (RANKL) mRNA in human multiple myeloma cells","volume":"130","author":"Heider","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022061702421679000_bib35","doi-asserted-by":"crossref","first-page":"e4947","DOI":"10.1371\/journal.pone.0004947","article-title":"Heparanase regulates levels of syndecan-1 in the nucleus","volume":"4","author":"Chen","year":"2009","journal-title":"PLoS One"},{"key":"2022061702421679000_bib36","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/leu.2008.159","article-title":"Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma","volume":"22","author":"Jakob","year":"2008","journal-title":"Leukemia"},{"key":"2022061702421679000_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2022061702421679000_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05018.x","article-title":"Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation","volume":"126","author":"Lai","year":"2004","journal-title":"Br J Haematol"},{"key":"2022061702421679000_bib39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"2022061702421679000_bib40","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702421679000_bib41","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428190309178765","article-title":"New insights in myeloma-induced osteolysis","volume":"44","author":"Barille-Nion","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2022061702421679000_bib42","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor \u03baB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2022061702421679000_bib43","first-page":"5438","article-title":"Receptor activator of nuclear factor-\u03baB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"2022061702421679000_bib44","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1158\/0008-5472.CAN-07-5889","article-title":"Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-\u03baB ligand","volume":"68","author":"Wilson","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702421679000_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00418-003-0589-1","article-title":"Heparanase mRNA expression during fracture repair in mice","volume":"120","author":"Saijo","year":"2003","journal-title":"Histochem Cell Biol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/21\/8329\/2640210\/8329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/21\/8329\/2640210\/8329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T06:27:42Z","timestamp":1655447262000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/70\/21\/8329\/559854\/Heparanase-Enhances-Local-and-Systemic-Osteolysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,31]]},"references-count":45,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2010,10,31]]},"published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-2179","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6502191.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502191","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22388280.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388280","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,31]]}}}